The World Health Organization has issued a comprehensive and definitive reminder to all Member States party to the WHO Framework Convention on Tobacco Control regarding their legal and public health obligations concerning heated tobacco products. As the global marketplace sees a proliferation of alternative nicotine delivery systems, public health authorities are increasingly pressed to clarify the regulatory boundaries governing these devices. The international public health body emphasizes that heated tobacco products, commonly known as HTPs, fall unequivocally under the regulatory scope of the WHO FCTC, a treaty ratified by a vast majority of nations worldwide to combat the global tobacco epidemic.

Under the framework of Decision FCTC/COP8(22), the global health agency underscores that HTPs are, by definition, tobacco products. Consequently, all stringent measures, restrictions, and prohibitions applicable to conventional cigarettes apply with equal force to heated alternatives. Particular emphasis is placed on Article 13.4(a) of the convention, which legally binds participating state parties to enact total bans on all forms of commercial tobacco advertising, promotion, and sponsorship. This prohibition specifically targets marketing tactics that present a tobacco product through means that are false, misleading, deceptive, or capable of creating an erroneous impression regarding the product’s characteristics, health effects, inherent hazards, or toxic emissions.

Background Context of the Rise of Heated Tobacco Products

The emergence of heated tobacco products represents a significant shift in the strategies employed by the global tobacco industry. Unlike traditional combustible cigarettes, which burn tobacco at high temperatures to generate smoke, HTPs utilize electronic heating mechanisms designed to bake processed tobacco leaves at lower temperatures. This process generates an aerosol containing nicotine and various chemical additives for the user to inhale.

For decades, the global tobacco landscape was dominated by traditional cigarettes, cigars, and pipe tobacco. However, declining smoking rates in developed nations, driven by rigorous public health campaigns, heavy taxation, and indoor smoking bans, compelled transnational tobacco companies to invest heavily in research and development. The goal was to engineer alternative nicotine delivery systems marketed as modern, sophisticated, and potentially less hazardous options for adult smokers who are either unwilling or unable to quit nicotine entirely.

These products entered various international markets with branding campaigns that often emphasized technological innovation, sleek design, and reduced visibility of smoke and ash. Public health researchers note that this aesthetic modernization has often been accompanied by subtle messaging that positions HTPs as a transitional tool or a modernized alternative, raising significant concerns among regulatory bodies regarding their potential to undermine decades of progress in tobacco control.

Evaluating the Toxicological Profile of HTP Aerosols

A central pillar of the public health agency’s advisory focuses on the complex chemical composition of emissions generated by heated tobacco devices. Industry proponents frequently argue that because these devices heat rather than burn tobacco, they produce lower quantities of certain harmful and potentially harmful constituents compared to conventional cigarette smoke.

However, public health toxicologists and international research institutions caution against equating a reduction in specific chemical yields with overall product safety. The international health authority reiterates that reducing exposure to a select group of harmful chemicals does not render heated tobacco products harmless, nor does it equate to a verifiable reduction in overall risk to human health.

Comprehensive independent laboratory analyses have revealed troubling findings regarding the aerosol composition of various HTP brands. While levels of certain combustion-related toxins may be lower due to the absence of active fire and high-temperature burning, other toxic chemicals are present at significantly higher levels in HTP aerosols than in conventional cigarette smoke. Furthermore, chemical analyses have identified the presence of entirely novel toxins in HTP emissions that do not exist in conventional cigarette smoke at all.

To date, the long-term clinical and epidemiological implications of chronic human exposure to these unique, high-concentration or novel toxins remain entirely unknown. Public health officials emphasize that without rigorous, long-term independent studies tracking cohorts of users over decades, any assertion of reduced risk is scientifically premature and potentially deceptive to consumers who may interpret reduced chemical exposure as a clean bill of health.

Chronology of Regulatory Milestones and the US FDA Decision

The global debate surrounding the regulatory classification and commercial authorization of heated tobacco systems reached a prominent milestone on July 7, 2020. On this date, the United States Food and Drug Administration authorized the marketing of a prominent heated tobacco product—the IQOS Tobacco Heating System, manufactured by Philip Morris International—under the provisions of the Federal Food, Drug, and Cosmetic Act.

This legislative act mandates that all new tobacco products must undergo a rigorous pre-market evaluation process before they can be legally manufactured, imported, or distributed within the United States market. Within the regulatory framework of the United States, manufacturers can seek authorization under two distinct pathways: as a new tobacco product or, alternatively, through a modified risk tobacco product application.

The authorization granted by the US regulatory agency in July 2020 was heavily scrutinized by international public health observers. In its official public statements accompanying the decision, the US agency explicitly articulated strict boundaries regarding what the authorization did and did not signify.

Crucially, the regulatory body stated that despite the marketing authorization, the products in question are fundamentally not safe, nor are they formally approved by the agency in the traditional sense applied to pharmaceutical drugs or medical devices. The exposure modification orders issued by the agency strictly prohibited the manufacturing company from making any modified risk claims that would suggest the product reduced the risk of tobacco-related diseases. Furthermore, the agency barred any express or implied statements that could mislead consumers into believing the products were endorsed, approved, or deemed safe for human consumption by the federal government.

Moreover, the US regulatory framework imposed strict post-market surveillance obligations on the manufacturer. The company was legally required to monitor youth awareness, initiation, and usage patterns to ensure that the commercialization of these products did not trigger unintended consequences among minors and young adults. Regular reporting mechanisms were established to keep federal regulators continuously informed of corporate efforts to curtail youth access and exposure to the marketing of these devices.

International Discrepancies in Regulatory Frameworks and Global Implications

The marketing authorization granted in the United States highlights a significant divergence in regulatory approaches across the globe. Public health experts emphasize that the US authorization was granted under temporary market provisions and was based strictly on statutory factors specific to the legal and domestic framework of the United States.

A critical factor in the international regulatory landscape is that the United States is not a Party to the WHO Framework Convention on Tobacco Control. Consequently, domestic regulatory decisions made within the US legal context do not supersede, alter, or diminish the international legal obligations established under the global treaty. Member States that have ratified the FCTC remain bound by international law to implement comprehensive tobacco control policies that treat HTPs with the same rigor applied to conventional tobacco products.

When regulatory agencies or commercial entities promote HTPs primarily on the premise that they reduce exposure to a subset of harmful chemicals relative to conventional cigarettes, such claims can easily be misinterpreted by the public. Given that human health may be adversely affected by exposure to the additional or elevated toxins uniquely present in HTP aerosols, such messaging is classified by global health authorities as inherently misleading.

Public Health Analysis and Recommendations for Comprehensive Action

Independent public health analysts suggest that the proliferation of alternative tobacco and nicotine products poses a multifaceted challenge to global tobacco control strategies. On one hand, industry representatives frame these innovations as instruments of harm reduction for established adult smokers. On the other hand, public health advocates express profound concern that these products serve as a gateway to nicotine addiction for adolescents and young adults who might otherwise never have initiated tobacco use.

The dual threat of sustaining nicotine addiction among current smokers while simultaneously recruiting a new generation of young consumers has prompted international health authorities to urge a return to foundational tobacco control measures. All tobacco products, regardless of their heating technology or marketing presentation, inherently pose severe risks to human health.

To counter these emerging public health threats, the World Health Organization strongly recommends the full, uncompromised implementation of the WHO Framework Convention on Tobacco Control across all participating jurisdictions. Rigorous implementation of the treaty provides the legal and structural foundation necessary to support genuine smoking cessation attempts among current users while aggressively curbing initiation rates among non-users, with a specific focus on protecting children and teenagers.

Furthermore, international health guidelines emphasize that cessation strategies should rely on proven, evidence-based clinical interventions rather than unverified commercial alternatives. Recommended cessation pathways include structured brief advice delivered routinely by healthcare professionals during clinical encounters, accessible national toll-free quit lines, evidence-based nicotine replacement therapies, and innovative cessation support programs delivered directly to individuals via mobile text messaging technologies. Through comprehensive regulatory enforcement, transparent public education, and robust cessation support, global health authorities aim to protect populations from the evolving tactics of the modern tobacco industry.